日本lecanemab处方模式的初始现实世界经验:长寿改善与公平证据 (LIFE) 研究
Kengo Kawaguchi1,2, Megumi Maeda1, Futoshi Oda1
1Department of Health Care Administration and Management Graduate School of Medical Sciences Kyushu University Fukuoka Japan.
Alzheimer's & dementia (Amsterdam, Netherlands)
|February 25, 2026
概括
这项研究检查了日本早期lecanemab的使用情况,发现它被处方给有轻度损伤的老年女性. 早期停药率很低,这表明对这种抗粉样β抗体的谨慎采用.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据.
背景情况:
- 莱卡尼马布是一种抗粉样β抗体,已在全球获得批准.
- 在美国以外,lecanemab的真实世界人口和使用数据有限.
- 了解早期采用模式对于治疗策略至关重要.
研究的目的:
- 检查日本早期使用lecanemab的现实世界.
- 为了确定日本队列中lecanemab的停止率.
- 为了确定与lecanemab处方和停用相关的患者特征.
主要方法:
- 分析了来自日本18个市镇的索赔数据 (2023年12月 - 2024年9月).
- 鉴定lecanemab接受者和评估停止治疗 (≥42天处方间隔).
- 评估共变量,包括年龄,性别,认知分数 (MMSE,CDR) 和并发症.
主要成果:
- 确定了123名lecanemab接受者;中位数年龄76岁,73.2%是女性.
- 大多数患者都有轻度认知障碍 (MMSE ≥24: 60.9%;CDR 0.5: 79.3%).
- 停药率为每100个人月1.04,大多数发生在1.5个月内.
结论:
- 这是关于亚洲lecanemab使用的第一份报告,主要涉及轻度认知障碍的老年女性.
- 较低的早期停药率表明,日本对lecanemab的采用是谨慎的,但稳定的.
- 研究结果提供了关于lecanemab在新人口背景下的实际应用的重要见解.
相关概念视频
Longitudinal Research
13.5K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
13.5K
Clinical Trials
10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.9K
Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Bioavailability Study Design: Single Versus Multiple Dose Studies
283
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
283
Bioavailability Study Design: Healthy Subjects Versus Patients
190
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
190
Bioequivalence studies: Biowaivers
329
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
329


